Data from 5 Nordic registries cohorts in #OP0222: incidence of ILD is 🔽in bDMARD treated PsA vs. RA pts, irrespective of co-medication with MTX. I wonder about evolving dx/seropositivity in pts w/ respect to ILD. #EULAR2021 @RheumNow https://t.co/0qFuXcPhmO https://t.co/gTUUtw80Lv